OBodies Scientific Advisory Board
Emeritus Professor Dick Bellamy (Chair): (FRSNZ)
Emeritus Professor Dick Bellamy is a virologist and molecular cell biologist whose research career centred on the study of double-stranded RNA viruses, in particular rotaviruses, the principal agents of diarrhoeal disease in young children. Over his time as a full-time researcher he worked in the general area of the molecular biology of virus infection and the application of recombinant methods to the characterisation of viral gene products. This work involved a network of collaborators in Australia and the USA. Dick is a Fellow of the Academy of the Royal Society of New Zealand and recently retired from the University after serving 10 years as Dean of Science; before that he was Director of the School of Biological Sciences at the University of Auckland. Dick is a current Director of Auckland Uniservices Ltd and its subsidiary DNA Diagnostics Ltd - which he helped found. Dick also currently serves on two Uniservices Committees that deal with aspects of the commercialisation of university intellectual property.
Dr Mark Baker
Dr Mark Baker is an Associate Director, Translational Medicine and Pharmaceutics at Medicines for Malaria Venture, Geneva, Switzerland. Mark is a clinical pharmacologist working on the clinical development of antimalarial therapeutics from candidate selection to Phase IIa. Mark also provides pharmacometric guidance including PK/PD and PBPK modeling to aid translational approaches. Mark has worked for a diverse range of pharmaceutical companies including GSK and NovImmune where he was Director and Head of Clinical Pharmacology respectively. Mark has previously worked from preclinical to Phase III on chemical and biological therapeutics in the oncology, immunology and respiratory therapeutic areas. Mark was trained at the Universities of Auckland, NZ and Sheffield, UK. He also holds a degree in marine biology.
Peter is a BAppSc and MMgt(Tech) graduate with over 25 years experience in all aspects of medical science and business having held positions such as Head of Research and Development, Sales and Marketing Manager as well as running his own biotechnology commercialisation consultancy. He is a highly-skilled, scientifically-trained leader with a wide knowledge of the health, pharmaceutical and laboratory based businesses. He has extensive knowledge and experience in commercialisation of science with hands-on experience in developing and marketing technology-based products.
Professor Margaret Brimble: (MNZM, FRSNZ, FRSC, FRACI, FNZIC)
Margaret Brimble graduated MSc from The University of Auckland and was awarded a Commonwealth Scholarship to undertake PhD studies at Southampton University. In 1986 she was appointed as a lecturer at Massey University, NZ. After a visiting Professorship at the University of California, Berkeley, she moved to the University of Sydney in 1995 and was promoted to Reader in Organic Chemistry. In 1999 she took up the Chair of Organic and Medicinal Chemistry at The University of Auckland. Her research focuses on the synthesis of bioactive natural products (especially molecules derived from extreme environments and shellfish toxins) as novel anticancer, antibacterial and antiviral agents, the synthesis of alkaloids and peptidomimetics for the treatment of neurodegenerative disorders, and the synthesis of peptide components for melanoma vaccines. She developed the drug candidate NNZ2566 for Neuren Pharmaceuticals that is in phase 2b clinical trials for traumatic brain injury in partnership with the US Army. She is Chair of the Rutherford Foundation, a member of the Marsden Fund Council (Convenor of the Physical Sciences Panel), Past-President of the International Society of Heterocyclic Chemistry, a principal investigator in the Maurice Wilkins Centre for Molecular Biodiscovery and a member of the Organic and Biomolecular Chemistry Editorial Board. She has published 250+ papers and 11 patents. Previous awards include the 2007 L'Oreal-UNESCO Women in Science Laureate for Asia-Pacific in Materials Science, the 2008 World Class New Zealand Award (Research, Science, Technology and Academia), Member of the New Zealand Order of Merit (Queen's Honour), Federation of Asian Chemical Societies Distinguished Chemist Award and the NZIC Easterfield Medal.
In 2012 Professor Brimble was honoured by receiving three medals from The Royal Society of New Zealand. Prof Brimble was awarded the highest honour in science, the Rutherford Medal, for exceptional contributions to the advancement and promotion of public awareness, knowledge and understanding in addition to eminent research or technological practice. She also received the MacDiarmid Medal for outstanding scientific research that could have large human benefit and the Hector Medal for excellence in chemical sciences.
Dr Wayne Patrick
Dr Wayne Patrick is a Senior Lecturer in the Institute of Natural Sciences at Massey University. He joined the academic staff at Massey in October, 2007. His PhD is from the Department of Biochemistry at the University of Cambridge, and he spent four years as a post-doctoral fellow at Emory University (Atlanta, USA). Dr. Patrick has a track record of bringing evolutionary insights to problems in protein structure, function and engineering. Since returning from overseas, his research has attracted ~$2.8 million in contestable funding. This includes two grants from the Marsden Fund and a prestigious Rutherford Discovery Fellowship (2011). He has also successfully engineered and commercialised highly active variants of a commonly-used molecular biology enzyme (DNA ligase). This work led to him being named as the 2010 NZBio Young Biotechnologist of the Year, and he remains the only university-based scientist to have won the award.
Dr Peter Senter
Dr Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr Senter was recognized as the company's first Distinguished Fellow. He leads Seattle Genetics' chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr Senter received a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He is the Senior Editor of Bioconjugate Chemistry and serves on the Editorial Board of four scientific journals. Dr Senter is an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr Senter has authored more than 100 scientific publications and holds more than 20 patents.